This week our CSO Lars Johansson joined the SurfingNASH podcast together with Dr Stephen Harrison, Louise Campbell and Roger Green to discuss innovations in liver imaging and how this can support drug development in this field.
Listen to the podcast to learn more about:
- New advances in positron emission tomography (PET) targeting fibrosis and hepatic stellate cell activation to investigate disturbances in extracellular matrix homeostasis, important for the development of anti-fibrotic drugs
- How PET-tracers can be used to assess individual contribution of different components in combination treatments
- Using gadoxetate magnetic resonance imaging (MRI) to assess functioning hepatocytes, stepping away from assessing ‘what should not’ be in the liver and instead measure ‘what should’ be there
- The importance of looking holistically and dynamically at liver disease to move beyond liver biopsy
- How imaging of spleen volume can be used to assess hemodynamic effects and pressure in late-stage liver fibrosis
- The potential of integrating different imaging approaches in clinical trials to generate valuable insights to guide and speed up drug development programmes
Find the podcast here
This week’s episode featuring Lars Johansson, CSO at Antaros Medical: Season 2, Episode 50: “Dare to Dream”: The Exciting, Evolving World of Organ Imaging
About Surfing the NASH Tsunami podcast
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases. Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.